English | Español

Janssen
Press release submission | Dec 29, 2021

Janssen Submits Biologics License Application to U.S. FDA Seeking Approval of Teclistamab for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

Press release submission | Dec 22, 2021

FDA Approves Two New Indications for XARELTO® (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients

Press release submission | Aug 19, 2021

Janssen Presents Phase 1 Results for RYBREVANT™ (amivantamab-vmjw) in the Treatment of Patients with Advanced Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutations

Press release submission | May 21, 2021

RYBREVANT™ (amivantamab-vmjw) Receives FDA Approval as the First Targeted Treatment for Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
Press release submission | Jan 16, 2019

JANSSEN: Announces European Commission approval of ERLEADA®(apalutamide) for non-metastatic castration-resistant prostate cancer patients who are at high risk of developing metastatic disease

Press release submission | Dec 6, 2018

JANSSEN: DARZALEX® (daratumumab) Combination Regimens Show Positive Results for Newly Diagnosed and Relapsed Patients with Multiple Myeloma

Trending
+ Technology/Innovation
Patient Daily News Service | Oct 9, 2025

Babylon Health collapse raises questions about AI claims across industries
Patient Daily | Oct 9, 2025

Medfluence Advisors Marketing Expert: 'The conversations leading into AAO-HNSF are shaping how ENT practices approach growth and engagement'
Patient Daily | Oct 9, 2025

AI takes center stage at ASCENT ENT conference, reshaping marketing and operations
+ Pharmaceuticals
Patient Daily | Oct 8, 2025

American Lung Association launches campaign urging vaccinations against seasonal flu and respiratory illnesses